Sleep tight: Less overnight vital monitoring improves perception of sleep quality at hospital

Being woken in the middle of the night is an unpleasant experience for anyone, but especially patients in the hospital undergoing their nightly vital sign check. Researchers from Ohio State University conducted a study, published in Patient Experience Journal, on reported quality of sleep and patient’s satisfaction during as hospital stay where overnight vital signs were collected compared to when vitals were not taken.

Monitoring a patient’s vital signs during the night ensures the patient is on a stable path to recovery, but still requires for caregivers to interrupt patients sleep. This study analyzed the difference in reported sleep and satisfactions in patients that were woken every four hours for vital sign measurements and patients who didn't have their vital signs checked at night.

The study enrolled low-risk observational stay patients with a planned cardiac procedure and sorted 39 into a conventional group, where overnight vital signs were taken every four hours, and 41 into the intervention group, where vital signs were not taken. Participants were given a questionnaire to report their reported quality of sleep and satisfaction with their stay in the hospital.

Results showed more patients in the standard group reported good or excellent sleep at home while more intervention group patients rated good or excellent sleep in the hospital. Patients in the intervention group reported slightly better sleep than those in the standard group. Overall, there was no difference in satisfaction with hospital stay.

“With this proof of concept now safely implemented, it is our intention to implement further studies to broaden our inclusion criteria and population to encourage a restful and healing environment through the entire healthcare stay,” concluded first author Kevin Stiver, Ohio State University Medical Center.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.